Although dendrimers have not yet taken the drug industry by storm, biomedical research and industrial applications of these tiny, highly branched molecules continue to grow. Vivien Marx reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mamikunian, V. & Maebius, S. Nanotech IP Battles Worth Fighting. (Lux Research, Foley & Lardner, New York, June 2006).
Lux Research. The Nanotech Report, 5th edn. (Lux Research, New York) 2007.
Dobrovolskaia, M.A. et al. Molecular Pharmaceutics, published online, doi:10.1021/mp800032f, (30 May 2008).
Swanson, D.R. et al. New J. Chem. 7, 1368–1378 (2007).
Wiener, E.C. et al. Invest Radiol. 32, 748–54 (1997).
Vetterlein, K. et al. Electrophoresis 28, 3088–3099 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marx, V. Poised to branch out. Nat Biotechnol 26, 729–732 (2008). https://doi.org/10.1038/nbt0708-729
Issue Date:
DOI: https://doi.org/10.1038/nbt0708-729
